Issue 11
Lilly has five authorised trials in the EU system. None of them are the drugs it just bought.
CTIS returns five authorised brenipatide trials under Lilly. The assets it paid $3.8 billion for appear in the same register under their own names: BPL-003 with one Phase 2b that ended last June, VLS-01 with nothing.
Read the issue- Issue 10A clinician, not a company, runs Germany's psilocybin compassionate use programme
- Issue 9No European application on file for the world's most advanced psilocybin programme
- Issue 8Europe already pays for clinic-administered psychiatry. Just not for psychedelics.
- Issue 7Eli Lilly buys AtaiBeckley for $3.8B, and prices Europe out of psychedelic medicine
- Issue 6Issue 6 / Week of 7-13 July 2026